Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v14-EN Version v6-FR
Language English French
Date Updated 2024-02-28 2023-11-27
Drug Identification Number 02204266 02204266
Brand name DEXAMETHASONE-OMEGA DEXAMETHASONE-OMEGA
Common or Proper name Dexamethasone Sodium Phosphate Injection USP Dexamethasone Sodium Phosphate Injection USP
Company Name OMEGA LABORATORIES LIMITED OMEGA LABORATORIES LIMITED
Ingredients DEXAMETHASONE PHOSPHATE DEXAMETHASONE PHOSPHATE
Strength(s) 4MG 4MG
Dosage form(s) LIQUID LIQUID
Route of administration SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR SOFT TISSUE INJECTION INTRAVENOUS INTRAMUSCULAR INTRALESIONAL INTRA-ARTICULAR
Packaging size 10 x 1mL vial/fiole 10 x 1mL vial/fiole
ATC code H02AB H02AB
ATC description CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2023-11-27
Actual start date 2023-11-28 2023-11-28
Estimated end date 2024-01-18
Actual end date 2024-02-27
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments